Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.3%

2 terminated out of 38 trials

Success Rate

88.2%

+1.7% vs benchmark

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

7%

1 of 15 completed with results

Key Signals

1 with results88% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (12)
P 1 (3)
P 2 (11)
P 3 (2)

Trial Status

Completed15
Recruiting12
Active Not Recruiting3
Unknown3
Terminated2
Not Yet Recruiting2

Trial Success Rate

88.2%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (38)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT07209189Phase 2Recruiting

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT07343596Not ApplicableRecruitingPrimary

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

NCT06876038Phase 2Not Yet Recruiting

Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions

NCT07063212Phase 2Recruiting

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

NCT03082534Phase 2Completed

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

NCT05793151Not ApplicableRecruiting

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

NCT05798780Not ApplicableActive Not RecruitingPrimary

The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors

NCT02586207Phase 1Completed

Pembrolizumab in Combination With CRT for LA-SCCHN

NCT05757817Not ApplicableRecruiting

Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae

NCT05429099Phase 2RecruitingPrimary

Mandibular Reconstruction Preplanning (ViPMR)

NCT04330781Phase 2CompletedPrimary

Radiotherapy of Head and Neck Cancer Using an Intraoral Stent

NCT05740033Not ApplicableRecruiting

Radial Forearm Donor Site Closure

NCT04809324Not ApplicableRecruitingPrimary

Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers

NCT05337631Recruiting

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

NCT06728631Phase 2Active Not RecruitingPrimary

Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL

NCT06806683Active Not Recruiting

Predictive Tools in Head and Neck Cancer Patients Undergoing Radiotherapy

NCT06690918CompletedPrimary

Risk Factors Contributing to Oral Cancer in Patients at Dr. Hasan Sadikin General Hospital Bandung

NCT05369234Phase 3CompletedPrimary

Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis

NCT06407570Not Yet RecruitingPrimary

Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment

Scroll to load more

Research Network

Activity Timeline